Company intelligence / Profile preview

Beijing Brilliance Bio

Beijing, Beijing, China

Ownership: Private
Development stage: Other

Overview

Beijing Brilliance Bio is a Chinese biopharmaceutical company focused on the research, development, and commercialization of innovative antiviral therapies. The company primarily targets infectious diseases, with a significant emphasis on chronic Hepatitis B (HBV) and HIV. Its lead programs include novel small molecule inhibitors designed to provide more effective treatment options for patients with viral infections. Brilliance Bio operates out of Beijing and maintains a pipeline of candidates at various stages of clinical and preclinical development.

Therapeutic areas: Infectious Diseases
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Beijing Brilliance Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Beijing Brilliance Bio.

Explore the full profile